CGRP Inhibitors Market - Global CGRP Inhibitors Industry Analysis, Size, Share, Growth, Trends, and Forecast 2025-2032 -

The global CGRP Inhibitors Market is experiencing a significant transformation as the demand for targeted and effective migraine treatments continues to grow. According to the latest projections, the market is expected to expand from US$ 5.9 Bn in 2025 to an impressive US$ 11.4 Bn by 2032, progressing at a robust CAGR of 9.7%.

Table of Contents

1. Executive Summary

• 1.1. Global CGRP Inhibitors Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value, 2025
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Value Chain Analysis
• 2.4. List of Recent FDA-Approved CGRP Inhibitors
• 2.5. Pipeline Assessment
• 2.6. Prevalence of Migraine by Key Countries
• 2.7. Reimbursement Scenario
• 2.8. Porter's Five Forces Analysis
• 2.9. COVID-19 Impact Analysis
  • 2.9.1. Supply
  • 2.9.2. Demand
• 2.10. Impact of Ukraine-Russia Conflict
• 2.11. Economic Overview
  • 2.11.1. World Economic Projections
• 2.12. PESTLE Analysis

3. Global CGRP Inhibitors Market Outlook, 2019-2032

• 3.1. Global CGRP Inhibitors Market Outlook, by Drug Type, Value (US$ Bn), 2019-2032
  • 3.1.1. Key Highlights
    • 3.1.1.1. Monoclonal Antibodies
    • 3.1.1.2. CGRP Antagonists
• 3.2. Global CGRP Inhibitors Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
  • 3.2.1. Key Highlights
    • 3.2.1.1. Acute (Abortive)
    • 3.2.1.2. Preventative
• 3.3. Global CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
  • 3.3.1. Key Highlights
    • 3.3.1.1. Oral
    • 3.3.1.2. Injectable
    • 3.3.1.3. Nasal
• 3.4. Global CGRP Inhibitors Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
  • 3.4.1. Key Highlights
    • 3.4.1.1. Hospital Pharmacies
    • 3.4.1.2. Retail Pharmacies
    • 3.4.1.3. Online Pharmacies
• 3.5. Global CGRP Inhibitors Market Outlook, by Patient Demographics, Value (US$ Bn), 2019-2032
  • 3.5.1. Key Highlights
    • 3.5.1.1. Adult
    • 3.5.1.2. Geriatric
    • 3.5.1.3. Paediatric
• 3.6. Global CGRP Inhibitors Market Outlook, by Region, Value (US$ Bn), 2019-2032
  • 3.6.1. Key Highlights
    • 3.6.1.1. North America
    • 3.6.1.2. Europe
    • 3.6.1.3. Asia Pacific
    • 3.6.1.4. Latin America
    • 3.6.1.5. Middle East & Africa

4. North America CGRP Inhibitors Market Outlook, 2019-2032

• 4.1. North America CGRP Inhibitors Market Outlook, by Drug Type, Value (US$ Bn), 2019-2032
  • 4.1.1. Key Highlights
    • 4.1.1.1. Monoclonal Antibodies
    • 4.1.1.2. CGRP Antagonists
• 4.2. North America CGRP Inhibitors Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
  • 4.2.1. Key Highlights
    • 4.2.1.1. Acute (Abortive)
    • 4.2.1.2. Preventative
• 4.3. North America CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
  • 4.3.1. Key Highlights
    • 4.3.1.1. Oral
    • 4.3.1.2. Injectable
    • 4.3.1.3. Nasal
• 4.4. North America CGRP Inhibitors Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
  • 4.4.1. Key Highlights
    • 4.4.1.1. Hospital Pharmacies
    • 4.4.1.2. Retail Pharmacies
    • 4.4.1.3. Online Pharmacies
• 4.5. North America CGRP Inhibitors Market Outlook, by Patient Demographics, Value (US$ Bn), 2019-2032
  • 4.5.1. Key Highlights
    • 4.5.1.1. Adult
    • 4.5.1.2. Geriatric
    • 4.5.1.3. Paediatric
  • 4.5.2. BPS Analysis/Market Attractiveness Analysis
• 4.6. North America CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn), 2019-2032
  • 4.6.1. Key Highlights
    • 4.6.1.1. U.S. CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 4.6.1.2. U.S. CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 4.6.1.3. U.S. CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 4.6.1.4. U.S. CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 4.6.1.5. U.S. CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
    • 4.6.1.6. Canada CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 4.6.1.7. Canada CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 4.6.1.8. Canada CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 4.6.1.9. Canada CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 4.6.1.10. Canada CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
  • 4.6.2. BPS Analysis/Market Attractiveness Analysis

5. Europe CGRP Inhibitors Market Outlook, 2019-2032

• 5.1. Europe CGRP Inhibitors Market Outlook, by Drug Type, Value (US$ Bn), 2019-2032
  • 5.1.1. Key Highlights
    • 5.1.1.1. Monoclonal Antibodies
    • 5.1.1.2. CGRP Antagonists
• 5.2. Europe CGRP Inhibitors Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
  • 5.2.1. Key Highlights
    • 5.2.1.1. Acute (Abortive)
    • 5.2.1.2. Preventative
• 5.3. Europe CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
  • 5.3.1. Key Highlights
    • 5.3.1.1. Oral
    • 5.3.1.2. Injectable
    • 5.3.1.3. Nasal
• 5.4. Europe CGRP Inhibitors Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
  • 5.4.1. Key Highlights
    • 5.4.1.1. Hospital Pharmacies
    • 5.4.1.2. Retail Pharmacies
    • 5.4.1.3. Online Pharmacies
• 5.5. Europe CGRP Inhibitors Market Outlook, by Patient Demographics, Value (US$ Bn), 2019-2032
  • 5.5.1. Key Highlights
    • 5.5.1.1. Adult
    • 5.5.1.2. Geriatric
    • 5.5.1.3. Paediatric
  • 5.5.2. BPS Analysis/Market Attractiveness Analysis
• 5.6. Europe CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn), 2019-2032
  • 5.6.1. Key Highlights
    • 5.6.1.1. Germany CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 5.6.1.2. Germany CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 5.6.1.3. Germany CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 5.6.1.4. Germany CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 5.6.1.5. Germany CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
    • 5.6.1.6. U.K. CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 5.6.1.7. U.K. CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 5.6.1.8. U.K. CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 5.6.1.9. U.K. CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 5.6.1.10. U.K. CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
    • 5.6.1.11. France CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 5.6.1.12. France CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 5.6.1.13. France CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 5.6.1.14. France CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 5.6.1.15. France CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
    • 5.6.1.16. Italy CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 5.6.1.17. Italy CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 5.6.1.18. Italy CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 5.6.1.19. Italy CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 5.6.1.20. Italy CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
    • 5.6.1.21. Turkey CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 5.6.1.22. Turkey CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 5.6.1.23. Turkey CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 5.6.1.24. Turkey CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 5.6.1.25. Turkey CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
    • 5.6.1.26. Russia CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 5.6.1.27. Russia CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 5.6.1.28. Russia CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 5.6.1.29. Russia CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 5.6.1.30. Russia CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
    • 5.6.1.31. Rest of Europe CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 5.6.1.32. Rest of Europe CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 5.6.1.33. Rest of Europe CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 5.6.1.34. Rest of Europe CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 5.6.1.35. Rest of Europe CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
  • 5.6.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific CGRP Inhibitors Market Outlook, 2019-2032

• 6.1. Asia Pacific CGRP Inhibitors Market Outlook, by Drug Type, Value (US$ Bn), 2019-2032
  • 6.1.1. Key Highlights
    • 6.1.1.1. Monoclonal Antibodies
    • 6.1.1.2. CGRP Antagonists
• 6.2. Asia Pacific CGRP Inhibitors Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
  • 6.2.1. Key Highlights
    • 6.2.1.1. Acute (Abortive)
    • 6.2.1.2. Preventative
• 6.3. Asia Pacific CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
  • 6.3.1. Key Highlights
    • 6.3.1.1. Oral
    • 6.3.1.2. Injectable
    • 6.3.1.3. Nasal
• 6.4. Asia Pacific CGRP Inhibitors Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
  • 6.4.1. Key Highlights
    • 6.4.1.1. Hospital Pharmacies
    • 6.4.1.2. Retail Pharmacies
    • 6.4.1.3. Online Pharmacies
• 6.5. Asia Pacific CGRP Inhibitors Market Outlook, by Patient Demographics, Value (US$ Bn), 2019-2032
  • 6.5.1. Key Highlights
    • 6.5.1.1. Adult
    • 6.5.1.2. Geriatric
    • 6.5.1.3. Paediatric
  • 6.5.2. BPS Analysis/Market Attractiveness Analysis
• 6.6. Asia Pacific CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn), 2019-2032
  • 6.6.1. Key Highlights
    • 6.6.1.1. China CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 6.6.1.2. China CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 6.6.1.3. China CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 6.6.1.4. China CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 6.6.1.5. China CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
    • 6.6.1.6. Japan CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 6.6.1.7. Japan CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 6.6.1.8. Japan CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 6.6.1.9. Japan CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 6.6.1.10. Japan CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
    • 6.6.1.11. South Korea CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 6.6.1.12. South Korea CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 6.6.1.13. South Korea CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 6.6.1.14. South Korea CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 6.6.1.15. South Korea CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
    • 6.6.1.16. India CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 6.6.1.17. India CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 6.6.1.18. India CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 6.6.1.19. India CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 6.6.1.20. India CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
    • 6.6.1.21. Southeast Asia CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 6.6.1.22. Southeast Asia CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 6.6.1.23. Southeast Asia CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 6.6.1.24. Southeast Asia CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 6.6.1.25. Southeast Asia CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
    • 6.6.1.26. Rest of Asia Pacific CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 6.6.1.27. Rest of Asia Pacific CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 6.6.1.28. Rest of Asia Pacific CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 6.6.1.29. Rest of Asia Pacific CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 6.6.1.30. Rest of Asia Pacific CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
  • 6.6.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America CGRP Inhibitors Market Outlook, 2019-2032

• 7.1. Latin America CGRP Inhibitors Market Outlook, by Drug Type, Value (US$ Bn), 2019-2032
  • 7.1.1. Key Highlights
    • 7.1.1.1. Monoclonal Antibodies
    • 7.1.1.2. CGRP Antagonists
• 7.2. Latin America CGRP Inhibitors Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
  • 7.2.1. Key Highlights
    • 7.2.1.1. Acute (Abortive)
    • 7.2.1.2. Preventative
• 7.3. Latin America CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
  • 7.3.1. Key Highlights
    • 7.3.1.1. Oral
    • 7.3.1.2. Injectable
    • 7.3.1.3. Nasal
• 7.4. Latin America CGRP Inhibitors Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
  • 7.4.1. Key Highlights
    • 7.4.1.1. Hospital Pharmacies
    • 7.4.1.2. Retail Pharmacies
    • 7.4.1.3. Online Pharmacies
• 7.5. Latin America CGRP Inhibitors Market Outlook, by Patient Demographics, Value (US$ Bn), 2019-2032
  • 7.5.1. Key Highlights
    • 7.5.1.1. Adult
    • 7.5.1.2. Geriatric
    • 7.5.1.3. Paediatric
  • 7.5.2. BPS Analysis/Market Attractiveness Analysis
• 7.6. Latin America CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn), 2019-2032
  • 7.6.1. Key Highlights
    • 7.6.1.1. Brazil CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 7.6.1.2. Brazil CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 7.6.1.3. Brazil CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 7.6.1.4. Brazil CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 7.6.1.5. Brazil CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
    • 7.6.1.6. Mexico CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 7.6.1.7. Mexico CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 7.6.1.8. Mexico CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 7.6.1.9. Mexico CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 7.6.1.10. Mexico CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
    • 7.6.1.11. Argentina CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 7.6.1.12. Argentina CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 7.6.1.13. Argentina CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 7.6.1.14. Argentina CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 7.6.1.15. Argentina CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
    • 7.6.1.16. Rest of Latin America CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 7.6.1.17. Rest of Latin America CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 7.6.1.18. Rest of Latin America CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 7.6.1.19. Rest of Latin America CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 7.6.1.20. Rest of Latin America CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
  • 7.6.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa CGRP Inhibitors Market Outlook, 2019-2032

• 8.1. Middle East & Africa CGRP Inhibitors Market Outlook, by Drug Type, Value (US$ Bn), 2019-2032
  • 8.1.1. Key Highlights
    • 8.1.1.1. Monoclonal Antibodies
    • 8.1.1.2. CGRP Antagonists
• 8.2. Middle East & Africa CGRP Inhibitors Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
  • 8.2.1. Key Highlights
    • 8.2.1.1. Acute (Abortive)
    • 8.2.1.2. Preventative
• 8.3. Middle East & Africa CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
  • 8.3.1. Key Highlights
    • 8.3.1.1. Oral
    • 8.3.1.2. Injectable
    • 8.3.1.3. Nasal
• 8.4. Middle East & Africa CGRP Inhibitors Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
  • 8.4.1. Key Highlights
    • 8.4.1.1. Hospital Pharmacies
    • 8.4.1.2. Retail Pharmacies
    • 8.4.1.3. Online Pharmacies
• 8.5. Middle East & Africa CGRP Inhibitors Market Outlook, by Patient Demographics, Value (US$ Bn), 2019-2032
  • 8.5.1. Key Highlights
    • 8.5.1.1. Adult
    • 8.5.1.2. Geriatric
    • 8.5.1.3. Paediatric
  • 8.5.2. BPS Analysis/Market Attractiveness Analysis
• 8.6. Middle East & Africa CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn), 2019-2032
  • 8.6.1. Key Highlights
    • 8.6.1.1. GCC CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 8.6.1.2. GCC CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 8.6.1.3. GCC CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 8.6.1.4. GCC CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 8.6.1.5. GCC CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
    • 8.6.1.6. South Africa CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 8.6.1.7. South Africa CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 8.6.1.8. South Africa CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 8.6.1.9. South Africa CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 8.6.1.10. South Africa CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
    • 8.6.1.11. Egypt CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 8.6.1.12. Egypt CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 8.6.1.13. Egypt CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 8.6.1.14. Egypt CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 8.6.1.15. Egypt CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
    • 8.6.1.16. Nigeria CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 8.6.1.17. Nigeria CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 8.6.1.18. Nigeria CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 8.6.1.19. Nigeria CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 8.6.1.20. Nigeria CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
    • 8.6.1.21. Rest of Middle East & Africa CGRP Inhibitors Market by Drug Type, Value (US$ Bn), 2019-2032
    • 8.6.1.22. Rest of Middle East & Africa CGRP Inhibitors Market by Treatment Type, Value (US$ Bn), 2019-2032
    • 8.6.1.23. Rest of Middle East & Africa CGRP Inhibitors Market by Route of Administration, Value (US$ Bn), 2019-2032
    • 8.6.1.24. Rest of Middle East & Africa CGRP Inhibitors Market by Distribution Channel, Value (US$ Bn), 2019-2032
    • 8.6.1.25. Rest of Middle East & Africa CGRP Inhibitors Market by Patient Demographics, Value (US$ Bn), 2019-2032
  • 8.6.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

• 9.1. Company Market Share Analysis, 2025
• 9.2. Competitive Dashboard
• 9.3. Company Profiles
  • 9.3.1. Pfizer Inc.
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Product Portfolio
    • 9.3.1.3. Financial Overview
    • 9.3.1.4. Business Strategies and Development
  • 9.3.2. AbbVie Inc.
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Product Portfolio
    • 9.3.2.3. Financial Overview
    • 9.3.2.4. Business Strategies and Development
  • 9.3.3. Eli Lilly and Company
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Product Portfolio
    • 9.3.3.3. Financial Overview
    • 9.3.3.4. Business Strategies and Development
  • 9.3.4. Teva Pharmaceutical Industries Ltd.
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Product Portfolio
    • 9.3.4.3. Financial Overview
    • 9.3.4.4. Business Strategies and Development
  • 9.3.5. Lundbeck A/S
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Product Portfolio
    • 9.3.5.3. Financial Overview
    • 9.3.5.4. Business Strategies and Development
  • 9.3.6. Amgen Inc.
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Product Portfolio
    • 9.3.6.3. Financial Overview
    • 9.3.6.4. Business Strategies and Development

10. Appendix

• 10.1. Research Methodology
• 10.2. Report Assumptions
• 10.3. Acronyms and Abbreviations